- Home
- DXR vs BTAI Comparison
DXR vs BTAI Comparison
Compare DXR & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | BTAI |
|---|---|---|
| Founded | 1970 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.5M | 49.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | DXR | BTAI |
|---|---|---|
| Price | $12.25 | $1.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $25.00 | ★ $32.80 |
| AVG Volume (30 Days) | 4.3K | ★ 578.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.46 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | $66,306.00 | ★ $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $416.40 |
| P/E Ratio | $33.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.55 | $1.17 |
| 52 Week High | $14.15 | $9.26 |
Technical Indicators
Market Signals| Indicator | DXR | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 43.92 |
| Support Level | $12.11 | $1.82 |
| Resistance Level | $13.02 | $2.30 |
| Average True Range (ATR) | 0.47 | 0.17 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 6.75 | 11.80 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.